Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Third Line”

284 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 284 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02657551
What this trial is testing

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Dana-Farber Cancer Institute 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT04287829
What this trial is testing

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

Who this might be right for
Mesotheliomas Pleural
The Netherlands Cancer Institute 58
Testing effectiveness (Phase 2)Study completedNCT01124864
What this trial is testing

AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Who this might be right for
Non-small-cell Lung Cancer
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)UnknownNCT02296203
What this trial is testing

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 27
Post-approval studies (Phase 4)UnknownNCT03555526
What this trial is testing

Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection

Who this might be right for
H Pylori Infection
National Taiwan University Hospital 320
Testing effectiveness (Phase 2)Study completedNCT00105092
What this trial is testing

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Who this might be right for
Non-Small-Cell Lung Carcinoma
Eli Lilly and Company 50
Testing effectiveness (Phase 2)UnknownNCT05314101
What this trial is testing

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Who this might be right for
ImmunotherapyColorectal Cancer
Fujian Cancer Hospital 25
Testing effectiveness (Phase 2)Looking for participantsNCT06980532
What this trial is testing

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Liu Huang 42
Testing effectiveness (Phase 2)Study completedNCT00809796
What this trial is testing

A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

Who this might be right for
Colorectal Cancer
Oncozyme Pharma Inc. 15
Testing effectiveness (Phase 2)Looking for participantsNCT06652048
What this trial is testing

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Who this might be right for
Non-Small Cell Lung Cancer
Jialei Wang 60
Not applicableActive Not RecruitingNCT05487248
What this trial is testing

On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

Who this might be right for
Unresectable Locally Advanced Colorectal CancerMetastatic Colorectal CancerCandidate for Third-line or Subsequent Lines of Therapy
Jules Bordet Institute 103
Large-scale testing (Phase 3)Study completedNCT00080340
What this trial is testing

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Carcinoma
Telik 520
Large-scale testing (Phase 3)Looking for participantsNCT06908304
What this trial is testing

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small -Cell Lung
Maia Biotechnology 300
Testing effectiveness (Phase 2)Looking for participantsNCT05954429
What this trial is testing

Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

Who this might be right for
Colorectal Cancer
Fudan University 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03657641
What this trial is testing

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerColorectal Cancer Metastatic
University of Southern California 75
Testing effectiveness (Phase 2)Study completedNCT03254654
What this trial is testing

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast Cancer
Fudan University 66
Large-scale testing (Phase 3)Study completedNCT00057720
What this trial is testing

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Telik 440
Testing effectiveness (Phase 2)Looking for participantsNCT06728852
What this trial is testing

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)Recurrent or Metastatic Lung CancerThird-line and Beyond Therapy+1 more
Li-kun Chen 32
Very early researchNot Yet RecruitingNCT07458919
What this trial is testing

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Who this might be right for
Lung Cancer
Fuzhou General Hospital 94
Large-scale testing (Phase 3)UnknownNCT02332512
What this trial is testing

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu HengRui Medicine Co., Ltd. 417
Load More Results